Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain.

Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain.
One of the challenges for developing drugs addressing neurological disorders is getting enough of the therapy into the brain.
Exicure has proprietary technology that enhances the ability of a therapy to penetrate into cells and last longer compared to currently available types of drugs and Ipsen sees enough potential to begin a partnership on drugs for two rare neurological disorders with no therapeutic options.
According to deal terms announced Monday, Paris-based Ipsen will pay Exicure $20 million up front to begin the alliance.
In exchange, Ipsen gains exclusive options to license the Huntington’s disease and Angelman syndrome therapies that Exicure is developing with its proprietary technology.
To stay up to date with latest top stories, make sure to subscribe to this YouTube channel by clicking the button above this video!
Exicure will fund the drug discovery and development work.
If Ipsen exercises its option on one or more of the programs, it will take over responsibility for further development of the drugs, and commercialization if they are approved.